Home > About GAMMAGARD LIQUID > Choosing What's Best for You

Choosing What's Best for You: IV or SubQ Administration

With Ig treatment, your doctor and you can choose IV or SubQ administration for the treatment of PI. Your choice will shape your infusion experience, including where and how often you receive treatment and whether your healthcare professional administers your infusion.

There have been no head-to-head clinical studies conducted comparing these products. Please talk to your doctor about the appropriate treatment for you.

GAMMAGARD LIQUID - IV or SubQ Administration

Indicated for patients two years of age and older with primary immunodeficiency1

Intravenous (IV)1,2

Conventional SubQ1,2

Infused directly into the bloodstream through a vein Infused under the skin in the fatty tissues of the abdomen, thighs, upper arm, or lower back
Administered once every 3 to 4 weeks Administered once a week
Dose given in 1 site Dose given in multiple sites
The number of simultaneous sites should be limited to 8
Administration requires a healthcare professional Can be self-administered after patient is trained by a healthcare professional
Infused at hospital, clinic, or home with nurse present Infused at home after being trained

Can also be administered by a caregiver.

For more information regarding all Shire IG products, please visit Shire.com and MyIgSource.com.

References: 1. GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10% [Prescribing Information]. Westlake Village, CA: Baxalta US Inc. 2. Blaese RM, Bonilla FA, Stiehm ER, Younger ME, eds. Patient & Family Handbook for Primary Immunodeficiency Diseases. 5th ed. Towson, MD: Immune Deficiency Foundation; 2013.


  • Sign up to get access to experienced Patient and Nurse Advocates, insurance and financial support, useful tools, and more.
    Enroll Now
  • Ask an Advocate Questions about PI or PI treatments? Our trained Patient and Nurse Advocates can help, and asking your question is easy with our Ask An Advocate feature.
    Start Getting Answers
  • Insurance Questions? MyIgSource is available by phone to answer your questions and can assist you with insurance information regarding your treatment. Call 1-855-250-5111 to learn more.
    See More Information

Gammagard Liquid MyIgCoPayCard Program Terms and Conditions

This manufacturer's coupon program is not valid for prescriptions reimbursed, in whole or in part, by Medicaid, Medicare, Medigap, VA, DoD, TRICARE, or any other federal or state healthcare programs, including state pharmaceutical assistance programs, and where prohibited by the health insurance provider or by law

Shire's MyIgCoPayCard program provides a maximum total benefit of $5,000 for eligible out-of-pocket costs and expires 12 months from date of activation. Eligible costs include deductible, copayment, and co-insurance costs for eligible Shire IG (Immunoglobulin) products. Non-medication expenses, such as ancillary supplies or administration-related costs, are not eligible.

To be eligible, patients must: 1. be starting or receiving treatment with (and have current prescription for) an eligible Shire IG product with an ICD-10 for a diagnosis of Primary Immunodeficiency; and 2. have commercial insurance that covers medication costs for prescribed Shire IG product and allows for CoPay assistance; and 3. be two (2) years old or older.

Acceptance of this offer must be consistent with the terms of benefits provided by patient's health insurance provider.

Offer limited to one card per person and may not be combined with any other coupon, discount, prescription savings card, rebate, free trial, patient assistance, or other offer.

This program is only valid for residents of the United States.

Shire reserves the right to change or discontinue this program at any time without notice.

This is not health insurance.


Add to patient instructions:

If your insurance situation changes, it is your responsibility to notify MyIgSource's CoPay assistance program.

© 2017 Shire. All rights reserved.

SHIRE and the Shire Logo are registered trademarks of Shire Pharmaceutical Holdings Ireland Limited or its affiliates. Gammagard Liquid is a trademark or registered trademark of Baxalta Incorporated, a wholly owned, indirect subsidiary of Shire plc.

S30515 04/17

Please expand for Indication and Important Safety Information.

Selected Important Safety Information for GAMMAGARD LIQUID
  • GAMMAGARD LIQUID can cause decreased kidney function or kidney failure, blood clots in the heart, brain, lungs or elsewhere in the body. Call your healthcare professional or go to your emergency department right away if you have: Reduced urination, sudden weight gain, or swelling in your legs. These could be signs of a kidney problem. Pain, swelling, warmth, redness, or a lump in your legs or arms. These could be signs of a blood clot.
  • Do not take GAMMAGARD LIQUID if you have a known history of a severe allergic reaction to IgG or other blood products.